Amgen Inc. $AMGN Shares Sold by Horizon Investments LLC

robot
Abstract generation in progress

Horizon Investments LLC reduced its stake in Amgen Inc. by 41.3% in Q4 2025, selling over 24,000 shares but still retaining a significant holding valued at $11.203 million. This comes as Amgen exceeded its Q1 earnings expectations and issued a positive FY-2026 EPS guidance, alongside announcing a quarterly dividend of $2.52 per share. Despite some negative sentiment regarding potential FDA action and investor concerns about its obesity drug strategy, Amgen has garnered mostly “Buy” or “Hold” ratings from analysts, with a consensus target price of $357.54.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin